• Vaccine Ontology ID: VO_0004456
• Type: DNA vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Mouse
• Paramyosin gene engineering:
  • Type: DNA vaccine construction
  • Description: Vector pcDNA vector/Amp expressed the full-length cDNA encoding paramyosin of Chinese S. japonicum (Sjc97) (Zhou et al., 2000).
  • Detailed Gene Information: Click Here.
• Vector: pcDNA1/Amp (Zhou et al., 2000)
• Immunization Route: Intramuscular injection (i.m.)

• Vaccine Ontology ID: VO_0004457
• Type: DNA vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Mouse
• FABP gene engineering:
  • Type: DNA vaccine construction
  • Description: Vector pVAX1 expressed Schistosoma japonicum 14 kDa fatty acid binding protein (SjFABP) (Wei et al., 2009).
  • Detailed Gene Information: Click Here.
• Vector: pVAX1 (Wei et al., 2009)
• Immunization Route: Intramuscular injection (i.m.)

• Vaccine Ontology ID: VO_0004460
• Type: DNA vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Mouse
• Sj23 gene engineering:
  • Type: DNA vaccine construction
  • Description: Vector pVIVO2 co-expressed S. japonicum integral membrane protein Sj23 and murine cytokine IL-12 (Gan et al., 2004).
  • Detailed Gene Information: Click Here.
• Il12a gene engineering:
  • Type: DNA vaccine construction
  • Description: Vector pVIVO2 co-expressed S. japonicum integral membrane protein Sj23 and murine cytokine IL-12 (Gan et al., 2004).
  • Detailed Gene Information: Click Here.
• Vector: pVIVO2 (Gan et al., 2004)
• Immunization Route: Intramuscular injection (i.m.)

• Type: Recombinant vector vaccine
• Status: Research
• Antigen: The Sj-F1 antigen of S. japonicum (Wang et al., 2013).
• Vector: The bacterium Streptococcus gordonii is used as the vaccine vector, with the Streptococcus pyogenes protein M6 designed to surface-localize the S. japonicum antigen on S. gordonii (Wang et al., 2013).
• Immunization Route: intranasal immunization
• Description: Because chemotherapy is currently the main effective method to treat schistosomiasis, but it doesn't prevent reinfection, there has been a need to create a vaccine that can safely express the pathogenic antigen and elicit protection against the disease. This vectored vaccine has been shown to partially protect laboratory mice from S. japonicum challenge, making it a good candidate for schistosomiasis prevention (Wang et al., 2013).

• Vaccine Ontology ID: VO_0004782
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Baboon
• Preparation: Replication-defective adenoviral vector-based vaccine with optimized SjTPI (rAdV-SjTPI.opt) (Dai et al., 2014).
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Vaccine Immune Response Type: VO_0000286
• Efficacy: In three separate experiments, pCMV-Sjc97, inoculated intramuscularly three times at doses of 100 or 200 μg per C57BL/6 mouse, was found to provide significant worm reduction rates. In addition, there was a substantial reduction in the number of eggs present in the livers and spleens of the pCMV-Sjc97 immunized group when compared with the pCMV blank vector control groups. Therefore, preliminary results suggest pCMV-Sjc97 can confer protective immunity in C57BL/6 mice (Zhou et al., 2000).

Mouse Response

• Vaccine Immune Response Type: VO_0000286
• Efficacy: The mice inoculated intramuscularly with pVAX/SjFABP showed significant worm reduction rate of 22.94% (P < 0.05) and egg reduction rate of 30.23% when compared with the pVAX1 control group. The addition of the pVAX/mIL-18 plasmids dramatically enhanced protection with worm reduction rate of 36.92% and egg reduction rate of 43.23% (P < 0.05), compared to the pVAX/SjFABP group (Wei et al., 2009).

Mouse Response

• Vaccine Immune Response Type: VO_0000286
• Efficacy: A 45.53% reduction in worm burden as well as a 58.35% egg reduction rate were found in mice vaccinated with pVIVO2-IL12-Sj23. The multivalent DNA vaccine pVIVO2-IL12-Sj23 induced stronger protection than the monovalent vaccine pVIVO2-Sj23 (P<0.05) (Gan et al., 2004).

Mouse Response

• Vaccine Immune Response Type: VO_0000287
• Immune Response: The mice inoculated with the vaccine showed strong serum IgG, serum IgA, and saliva IgA antibodies against the antigen Sj-F1 (Wang et al., 2013).
• Challenge Protocol: The mice were challenged with the cercariae (parasitic larva) of S. japonicum (Wang et al., 2013).
• Efficacy: The mice immunized with the vaccine showed "significant protection" including a 21.45% reduction in the number of parasitic worms present and a 34.77% reduction in the number of eggs (Wang et al., 2013).
• Description: The protection received shows that the S. gordonii vector expressing S. japonicum is highly immunogenic and has potential to become a safe, effective vaccine against schistosomiasis (Wang et al., 2013).

Mouse Response

• Vaccination Protocol: Mice were randomly divided into different vaccination groups (16 mice/group) for intramuscular (i.m.), subcutaneous (s.c.) and oral immunization (o.i.). Groups consisted of vaccination with the adenoviral vector alone or without vaccination were used as vector or normal control, respectively (Dai et al., 2014).
• Vaccine Immune Response Type: VO_0003057
• Challenge Protocol: Each mouse was challenged with 40 ± 1 S. japonicum cercariae by abdominal skin penetration two weeks after the last vaccination (Dai et al., 2014).
• Efficacy: Results showed that intramuscular rAdV-SjTPI.opt induced Th1 biased immune responses in the host, while subcutaneous rAdV-SjTPI.opt induced Th2 predominant immune responses. Oral rAdV-SjTPI.opt induced low levels of immune responses and no significant protection. Intramuscular rAdV-SjTPI.opt provided a consistent and repeatable higher protective effect in mice (Dai et al., 2014).